Parkinson ’s Disease Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2018 – 2024

The report defines global Parkinson’s disease therapeutics market as the therapy used in the treatment of Parkinson's disease. Parkinson's disease is a long-term degenerative disorder of the nervous system that mainly affects the nerve cells in the brain.  Parkinson's has several symptoms including muscle stiffness, uncontrolled body movement, balance problems and improper motor movements. Presently Parkinson's disease is incurable. The treatment is only available to manage the symptoms of Parkinson’s.

Request a Discount on Standard Prices of this Premium Report @ https://www.infiniumglobalresearch.com/reports/request-discount/1503

Parkinson's is the second most common degenerative neurological disorder. According to the National Center for Biotechnology Information, PD affects 1% of the population above 60 years, each year. The growing prevalence of Parkinson's disease among the aged population drives the growth of Parkinson’s disease therapeutics market. In addition, rising geriatric population, growing environmental factors and genetic heredity are contributing to the growth of Parkinson’s disease therapeutics market.

Market Segmentation by Drug Class

Global Parkinson’s disease Therapeutics Market by Drug Class segmented as Carbidopa/Levodopa, Dopamine Receptor Agonists, Mao Inhibitors, Mao Inhibitors, Anticholinergics and Other Drugs. Among the drug class, Carbidopa/Levodopa medication is used to treat symptoms of Parkinson's disease. This medication changes into dopamine in the brain to control the movement. In addition, Dopamine Receptor Agonists has less potent than levodopa so they are beneficially used to treat symptoms for long periods of time. Newly developed therapeutics for the Parkinson's disease is getting approved by the Federal Drug Administration (FDA) that in turns to promote the growth of Parkinson’s disease therapeutics market.

Regional Analysis

Among the geographies, North America holds the maximum share in the Parkinson’s disease therapeutics market and expected to be the dominating region in this market over the forecast period. As per the Parkinson Association of the Carolinas, nearly 60,000 Americans are diagnosed with Parkinson’s disease each year. The growing prevalence of Parkinson’s disease in North America drives the growth of Parkinson’s disease therapeutics market in this region. In addition, Asia Pacific region is the fastest growing region in the Parkinson’s disease therapeutics market owing to the growth in geriatric population and developing healthcare infrastructure.

Competitive Landscape

The report provides profiles of the companies in the global Parkinson's disease therapeutics market such as GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck and Sun Pharma.

Read Detailed Index of full Research Study @ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-parkinsons-disease-therapeutics-market

About Infinium Global Research

Infinium Global Research and Consulting Solutions is started with a single motto of being a business partner of the first choice. We at Infinium work on the strengths of our clients to ensure we help them consolidate their market position. We firmly believe in the fact that ‘if you are able to develop newer opportunities then you find there is no dearth of opportunities for you. With our strategic research approaches and deep dive in the market segments, we try to find out new opportunities that our clients can encash with their existing resources. Our experts with over 100 years of cumulative experience in research offer the best in the industry services to our clients to ensure that they achieve their business goals.

Contact Us:

Infinium Global Research
Office No. 04, 06, Ganadhish Empire,
Rahatani Corner, Pune, MH 411027
Email: info@infiniumglobalresearch.com
Website: www.infiniumglobalresearch.com

This release was published on openPR.